08:00 , Dec 14, 2015 |  BC Week In Review  |  Company News

Plethora, Regent Pacific Group Ltd. deal

Urological disorder company Plethora said it and biopharma investment group Regent Pacific had reached “in principle” a deal whereby Regent would acquire the 70.12% of Plethora it does not already own. Plethora shareholders will receive...
08:00 , Nov 25, 2013 |  BC Week In Review  |  Clinical News

Prilocaine Lidocaine Plethora regulatory update

Plethora said the European Commission approved an MAA for Prilocaine Lidocaine Plethora to treat premature ejaculation. The company plans to launch the topical analgesic spray containing lidocaine and prilocaine in late 2014 and submit a...
07:00 , Oct 7, 2013 |  BioCentury  |  Finance

3Q Stock Wrap-Up: Make it a double

For the second time this year, all market cap segments closed the quarter in the black. Large caps valued at $5 billion and above gained ground for the fifth consecutive quarter. They added 12%, and...
07:00 , Sep 30, 2013 |  BC Week In Review  |  Clinical News

Lidocaine Prilocaine Plethora lidocaine/prilocaine regulatory update

EMA's CHMP issued a positive opinion recommending approval of an MAA from Plethora for Lidocaine Prilocaine Plethora lidocaine/prilocaine to treat primary premature ejaculation in adult men. Plethora said it expects a final decision from the...
07:00 , Sep 2, 2013 |  BC Week In Review  |  Company News

Plethora, Shionogi deal

Shionogi's Sciele Pharma Inc. subsidiary granted Plethora regulatory and commercialization rights to PSD502 in North and South America, Japan, Korea, China and Taiwan under an amended 2007 deal. Plethora now has rights to PSD502 worldwide....
08:00 , Mar 4, 2013 |  BC Week In Review  |  Company News

Plethora genitourinary news

Plethora said it will no longer finance its marketing subsidiary The Urology Co. to reduce operating costs and focus its efforts on the approval and commercialization of PSD502 . While revenues have grown since Plethora...
07:00 , Jul 16, 2012 |  BC Week In Review  |  Clinical News

PSD502 regulatory update

In June, Plethora said it submitted an MAA to EMA for PSD502 to treat premature ejaculation. The company expects a decision in 2H13 on the application. Plethora gained worldwide registration and commercialization responsibilities for PSD502,...
07:00 , Oct 3, 2011 |  BC Week In Review  |  Company News

Plethora, Shionogi deal

Plethora will assume worldwide registration and commercialization responsibilities for PSD502 , excluding North and South America, Japan, Korea, China and Taiwan, after it and Shionogi's Sciele Pharma Inc. subsidiary amended a 2007 deal. The deal...
07:00 , Aug 3, 2009 |  BC Week In Review  |  Clinical News

PSD502: Phase III data

In a double-blind, placebo-controlled, international Phase III trial in 240 patients, PSD502 met the 3 co-primary endpoints of improvement from baseline vs. placebo in IELT and the index of PE domains for ejaculatory control, sexual...
07:00 , Aug 3, 2009 |  BioCentury  |  Finance

Ebb & Flow

Cumberland Pharmaceuticals Inc. is hoping to capitalize on both the market upswing and the June FDA approval of its Caldolor IV ibuprofen to get an IPO out the door. The last substantial IPO was almost...